Long-term high density lipoprotein infusion ameliorates metabolic phenotypes of diabetic db/db mice

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 2, 2013, Pages 130-138

  Zhang, Qichun ^a,b   Wan, Rong ^a   Guo, Rui ^a   Jin, Lai ^a   Liu, Yunxin ^a   Li, Shengnan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Diabetic mellitus; Glucose; HDL; Metabolism syndrome

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; FATTY ACID; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSE; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; MALONALDEHYDE; MONOCYTE CHEMOTACTIC PROTEIN 1; RESISTIN; SYNAPSIN I;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME PHOSPHORYLATION; FOOD INTAKE; GASTROCNEMIUS MUSCLE; GLUCOSE BLOOD LEVEL; GLYCOGEN ANALYSIS; HISTOCHEMISTRY; IN VIVO STUDY; INFUSION; INSULIN RESISTANCE; LIPID METABOLISM; LIPID PEROXIDATION; LONG TERM CARE; MALE; METABOLIC PARAMETERS; MORPHOLOGY; MOUSE; NONHUMAN; PANCREAS ISLET; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT DURATION; WESTERN BLOTTING;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLYCOGEN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; LIPID METABOLISM; LIPID PEROXIDATION; LIPOPROTEINS, HDL; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; PHENOTYPE;

EID: 84873461899     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2372     Document Type: Article

References (32)

1. Drew BG, Duffy SJ, Formosa MF, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009; 119(15): 2103-2111.
2. Wu Y, Zhang R, Zhou C, et al. Enhanced expression of vascular cell adhesion molecule-1 by corticotrophin-releasing hormone contributes to progression of atherosclerosis in LDL receptor-deficient mice. Atherosclerosis 2009; 203(2): 360-370.
3. Link JJ, Rohatgi A, de Lemos JA. HDL cholesterol: physiology, pathophysiology, and management. Curr Probl Cardiol 2007; 32(5): 268-314.
4. Ceriello A, Testa R. Antioxidant anti-inflammatory treatment in type 2 diabetes. Diabetes Care 2009; 32(Suppl 2): S232-S236.
5. Abdin AA, Baalash AA, Hamooda HE. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers. J Diabetes Complications 2010; 24(3): 168-178.
6. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259(5091): 87-91.
7. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F, Franceschini G. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res 2003; 92(3): 330-337.
8. Borst SE, Lee Y, Conover CF, Shek EW, Bagby GJ. Neutralization of tumor necrosis factor-alpha reverses insulin resistance in skeletal muscle but not adipose tissue. Am J Physiol Endocrinol Metab 2004; 287(5): E934-938.
9. Patel S, Drew BG, Nakhla S, et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol 2009; 53(11): 962-971.
10. Galle J, Ochslen M, Schollmeyer P, Wanner C. Oxidized lipoproteins inhibit endothelium-dependent vasodilation. Effects of pressure and high-density lipoprotein. Hypertension 1994; 23(5): 556-564.
11. Abderrahmani A, Niederhauser G, Favre D, et al. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 2007; 50(6): 1304-1314.
12. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002; 347(19): 1483-1492.
13. Roehrich ME, Mooser V, Lenain V, et al. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 2003; 278(20): 18368-18375.
14. Rutti S, Ehses JA, Sibler RA, et al. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 2009; 150(10): 4521-4530.
15. Brunham LR, Kruit JK, Pape TD, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007; 13(3): 340-347.
16. Rapizzi E, Taddei ML, Fiaschi T, Donati C, Bruni P, Chiarugi P. Sphingosine 1-phosphate increases glucose uptake through trans-activation of insulin receptor. Cell Mol Life Sci 2009; 66(19): 3207-3218.
17. Han R, Lai R, Ding Q, et al. Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 2007; 50(9): 1960-1968.
18. Peterson SJ, Kim DH, Li M, et al. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J Lipid Res 2009; 50(7): 1293-1304.
19. Peterson SJ, Drummond G, Kim DH, et al. L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J Lipid Res 2008; 49(8): 1658-1669.
20. Nieuwdorp M, Vergeer M, Bisoendial RJ, et al. Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. Diabetologia 2008; 51(6): 1081-1084.
21. Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest 1989; 60(3): 455-461.
22. Sumi M, Sata M, Miura S, et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27(4): 813-818.
23. Halse R, Fryer LG, McCormack JG, Carling D, Yeaman SJ. Regulation of glycogen synthase by glucose and glycogen: a possible role for AMP-activated protein kinase. Diabetes 2003; 52(1): 9-15.
24. Roach PJ. Glycogen and its metabolism. Curr Mol Med 2002; 2(2): 101-120.
25. Seetharam D, Mineo C, Gormley AK, et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res 2006; 98(1): 63-72.
26. Carlson LA. Effect of a single infusion of recombinant propolipoprotein A-I liposomes [synthetic HDL] on plasma lipoproteins in patients with low high density lipoprotein cholesterol. Nutrition Metabolism Cardiovasc Dis 1995; 5: 85-91.
27. Calkin AC, Drew BG, Ono A, et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009; 120(21): 2095-2104.
28. Zhang Q, Zhang Y, Feng H, et al. High density lipoprotein (HDL) promotes glucose uptake in adipocytes and glycogen synthesis in muscle cells. PLoS One 2011; 6(8): e23556.
29. Henriksen EJ, Dokken BB. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets 2006; 7(11): 1435-1441.
30. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008; 94(2): 206-218.
31. Wadham C, Albanese N, Roberts J, et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 2004; 109(17): 2116-2122.
32. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002; 13(1): 51-59.